Patecki Margret, Lehmann Gabriele, Bräsen Jan Hinrich, Schmitz Jessica, Bertram Anna, Berthold Lars Daniel, Haller Hermann, Gwinner Wilfried
Department of Nephrology and Hypertension, Hannover Medical School, Carl-Neuberg-Straße 1, 30635, Hannover, Germany.
Division of Rheumatology/Osteology, Department of Internal Medicine III, Friedrich-Schiller-University of Jena, Erlanger Allee 101, 07747, Jena, Germany.
BMC Nephrol. 2017 Apr 21;18(1):137. doi: 10.1186/s12882-017-0556-z.
Calciphylaxis is a serious complication in patients with chronic kidney disease associated mineral and bone disorder. It can occur in conditions with low and high bone turnover. So far, there are no definite diagnostic and therapeutic guidelines which may prevent the devastating outcome in many calciphylaxis patients. We report a case which clearly illustrates that knowledge of the underlying bone disorder is essential for a directed treatment. Based on this experience we discuss a systematic diagnostic and therapeutic approach in patients with calciphylaxis.
We report a patient with severe calciphylaxis. Initial evaluation showed an elevated serum parathormone concentration and a bone-specific alkaline phosphatase activity in the upper normal range; however, the bone biopsy clearly showed adynamic bone disease. Extended dialysis with low calcium dialysate concentration and citrate anticoagulation, and administration of teriparatide led to a further increase in bone-specific alkaline phosphatase activity and most importantly, resulted in an activated bone turnover as confirmed by a second bone biopsy 11 weeks later.
This case illustrates that laboratory tests cannot reliably differentiate between high and low bone turnover in calciphylaxis patients. More importantly, this case highlights the fact that specific therapies that alter bone metabolism cannot be applied without knowledge of the bone status. On this background, we suggest that bone biopsies should be an integral part in the diagnosis and therapeutic decision in these patients and should be evaluated in further studies.
钙化防御是慢性肾脏病矿物质和骨异常患者的一种严重并发症。它可发生于骨转换率低和高的情况下。到目前为止,尚无明确的诊断和治疗指南可预防许多钙化防御患者的灾难性后果。我们报告一例病例,该病例清楚地表明了解潜在的骨病对于针对性治疗至关重要。基于这一经验,我们讨论了钙化防御患者的系统诊断和治疗方法。
我们报告一例严重钙化防御患者。初始评估显示血清甲状旁腺激素浓度升高,骨特异性碱性磷酸酶活性在正常上限范围内;然而,骨活检明确显示为骨无动力症。采用低钙透析液浓度和枸橼酸盐抗凝进行延长透析,并给予特立帕肽,导致骨特异性碱性磷酸酶活性进一步升高,最重要的是,11周后第二次骨活检证实骨转换活跃。
该病例表明,实验室检查不能可靠地区分钙化防御患者的高骨转换和低骨转换。更重要的是,该病例突出了一个事实,即在不了解骨状态的情况下不能应用改变骨代谢的特异性疗法。在此背景下,我们建议骨活检应成为这些患者诊断和治疗决策的一个组成部分,并应在进一步研究中进行评估。